Modulatory effects of bortezomib on host immune cell functions

Samuel Troy Pellom, Duafalia Fred Dudimah, Menaka Chanu Thounaojam, Thomas Joseph Sayers, Anil Shanker

Research output: Contribution to journalReview articlepeer-review

44 Scopus citations


Bortezomib is an inhibitor of the ubiquitin-proteasome proteolytic pathway responsible for intracellular protein turnover. Cellular proteins controlled by this pathway represent a diverse group of potential therapeutic targets, particularly in cancer cells, which exploit this proteasomal pathway to promote their growth and diminish apoptosis. Along with inhibiting the proteasome and thus sensitizing tumor cells to apoptosis, bortezomib may also have multiple effects on the host immune responses. This review summarizes the effects that bortezomib may play on immune cell subsets in various disease states in modifying lymphocyte receptors, ligands, the expression of various cytokines and chemokines and their downstream signaling. We also propose steps that can be taken to refine combinatorial strategies that include bortezomib to improve current immunotherapeutic approaches.

Original languageEnglish (US)
Pages (from-to)1011-1022
Number of pages12
Issue number9
StatePublished - Sep 2015
Externally publishedYes


  • B cells
  • NK cells
  • T cells
  • bortezomib
  • chemokine
  • cytokine
  • dendritic cells
  • immunity
  • inflammation
  • ligands
  • lymphocyte receptors

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology


Dive into the research topics of 'Modulatory effects of bortezomib on host immune cell functions'. Together they form a unique fingerprint.

Cite this